Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant RSV Vaccine (CHO Cell) in Adults Aged 60 and Above
NCT07272434Phase 3Recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus infection (RSV), sponsored by MAXVAX Biotechnology. Started Oct 2025; status: recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07272434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272434.